Skip to main content
  • Sections
  • Search

Center for Strategic & International Studies

User menu

  • Subscribe
  • Sign In

Topics

  • Climate Change
  • Cybersecurity and Technology
    • Cybersecurity
    • Data Governance
    • Intellectual Property
    • Intelligence, Surveillance, and Privacy
    • Military Technology
    • Space
    • Technology and Innovation
  • Defense and Security
    • Counterterrorism and Homeland Security
    • Defense Budget
    • Defense Industry, Acquisition, and Innovation
    • Defense Strategy and Capabilities
    • Geopolitics and International Security
    • Long-Term Futures
    • Missile Defense
    • Space
    • Weapons of Mass Destruction Proliferation
  • Economics
    • Asian Economics
    • Global Economic Governance
    • Trade and International Business
  • Energy and Sustainability
    • Energy, Climate Change, and Environmental Impacts
    • Energy and Geopolitics
    • Energy Innovation
    • Energy Markets, Trends, and Outlooks
  • Global Health
    • Family Planning, Maternal and Child Health, and Immunizations
    • Multilateral Institutions
    • Health and Security
    • Infectious Disease
  • Human Rights
    • Building Sustainable and Inclusive Democracy
    • Business and Human Rights
    • Responding to Egregious Human Rights Abuses
    • Civil Society
    • Transitional Justice
    • Human Security
  • International Development
    • Food and Agriculture
    • Governance and Rule of Law
    • Humanitarian Assistance
    • Human Mobility
    • Private Sector Development
    • U.S. Development Policy

Regions

  • Africa
    • North Africa
    • Sub-Saharan Africa
  • Americas
    • Caribbean
    • North America
    • South America
  • Arctic
  • Asia
    • Afghanistan
    • Australia, New Zealand & Pacific
    • China
    • India
    • Japan
    • Korea
    • Pakistan
    • Southeast Asia
  • Europe
    • European Union
    • NATO
    • Post-Soviet Europe
    • Turkey
  • Middle East
    • The Gulf
    • Egypt and the Levant
    • North Africa
  • Russia and Eurasia
    • The South Caucasus
    • Central Asia
    • Post-Soviet Europe
    • Russia

Sections menu

  • Programs
  • Experts
  • Events
  • Analysis
    • Blogs
    • Books
    • Commentary
    • Congressional Testimony
    • Critical Questions
    • Interactive Reports
    • Journals
    • Newsletter
    • Reports
    • Transcript
  • Podcasts
  • iDeas Lab
  • Transcripts
  • Web Projects

Main menu

  • About Us
  • Support CSIS
    • Securing Our Future
Photo: Global Giving Foundation
Blog Post - Smart Global Health
Share
  • LinkedIn
  • Facebook
  • Twitter
  • Email
  • Printfriendly.com

Achieving TB Milestones Through Last Mile Delivery in India

By Deen L. Garba

May 25, 2017

India has the world’s largest burden of tuberculosis. The government has recently committed to raise TB as a national priority. With such a colossal burden, India may do well to scale up its promising health innovations. In this GHPC blog, Deen Garba describes how one organization in India has used last mile delivery to make gains in TB.
 
The magnitude of India’s tuberculosis crisis is staggering. India has the largest burden of tuberculosis globally, with an estimated 2.8 million cases, and TB is the number one cause of death among its citizens. Recent signs suggest that the government of Prime Minister Narendra Modi appreciates the gravity of the situation. During the WHO Southeast Asia Regional Meeting in March, India’s Minister of Health JP Nadda pledged to end the country’s TB epidemic by 2025, and said an aggressive strategy to do this was being finalized. If India is to achieve such a lofty goal then a bold, disruptive approach to TB will be required; one that addresses the threat of Multidrug-Resistant (MDR) TB and finds ways to navigate India’s fragmented health system. In late March, I traveled to India with CSIS to explore how India’s rapid economic growth has led to significant health gains and discovered how one organization is achieving results in TB by taking treatment directly to patients.
 
India has more than 27 percent of the world’s burden of TB. The economic costs incurred equate to $300 million USD in lost wages per year, and a $23 billion USD indirect cost to the Indian economy due to staff absenteeism and lost productivity. Patients are often deterred from seeking treatment by social stigma and poor access to quality services in the public sector. Most patients opt for treatment from formal or informal providers in the private health system, but because this sector is largely unregulated and data gathering is poor, tracking patients throughout their course of treatment is difficult.
 
Government policies place additional barriers in the way of treatment.  Patients with MDR-TB were given hope when a new drug, Bedaquiline, was approved for use but limited stocks mean the drug is only available in six states across the country, and patients must have lived in one of these states for three years to be eligible for treatment. (These regulations faced a legal challenge in January, when the high court in Delhi ruled that an exception must be made for a seriously ill MDR-TB sufferer who did not meet the residency requirements). 
 
A handful of Indian health experts are finding creative solutions to tackle the TB crisis. Located in the South Delhi neighborhood of Sarita Vihar, Operation ASHA (OpASHA) is an NGO that has provided TB treatment and educational services to 14.6 million people worldwide since 2006. How? By taking the World Health Organization’s standard TB treatment model, DOTS (Directly Observed Therapy Short Course) directly to the hearts of the slums through its mobile clinics. OpASHA’s pragmatic, community-based approach enables patients to more easily adhere to their treatment regimens, and this has led to fewer than three percent of patients missing their doses each day, compared to 36 percent in the public health system.
 
For years, the number of projected TB cases in India has increased, while detection has remained low. This can largely be attributed to the fact that patients from the country’s urban slums and rural communities often do not elect to enter the public healthcare system. Faced with a choice between traveling to distant health facilities to take a single dose of medication and going to work to provide food for their families, patients naturally tend to choose the latter. We met with Dr. Shelly Batra, President of OpASHA, who explained that their approach saves time and money for patients by delivering medication directly to their doorstep or to accessible collection points in their neighborhood.  
 
OpASHA has also partnered with Microsoft to develop “eCompliance,” a monitoring system to help ensure adherence to TB medication. Under this method, treatment can only be administered when both the health worker and patient provide their fingerprints on a mobile reader. The eCompliance system has reduced the default rate—the number of patients failing to complete treatment—to less than 1 percent.
 
These costs compare favorably to more traditional approaches. The United States Agency for International Development (USAID) has helped procure GeneXpert machines, known locally by the non-proprietary name of CBNAAT (cartridge-based nucleic acid amplification test), for the rapid diagnosis of TB across India. Yet, despite being lauded as the preferred diagnostic for TB, each machine costs roughly $20,000 USD. Simply purchasing more machines to place in urban slums is not the most cost-effective solution, despite the relative success of CBNAAT as an initial TB diagnostic in Indian public health facilities.
 
Globally, NGOs spend an average of $852 USD detecting each patient. By contrast, Operation ASHA spends $80 USD on both detection and treatment, with an eCompliance per-patient cost of $3.55 USD, or 162 Indian Rupees. Not only are costs substantially reduced through eCompliance, but the technology can also be adapted for other purposes. Several states in India have repurposed it to track everything from school attendance, treatment for hypertension, and the detection and management of diabetes. 
 
Our trip to India illuminated some of India’s most promising health innovations. Over 80 percent of India’s citizens continue to rely on a virtually unregulated private healthcare system. Instead of having patients travel to such clinics, Operation ASHA’s model seems practical: treatment should be taken directly to the patient. While this approach is certainly not the only solution to a TB epidemic that requires a multifaceted approach, it does offer a compelling example of how last mile delivery can be a financially pragmatic approach to treating those with TB in the world’s most difficult-to-reach locales. Additional innovations such as OpASHA that prioritize last mile delivery could prove effectual in realizing India’s ambitious hopes of eliminating TB by 2025.

Media Queries
Contact H. Andrew Schwartz
Chief Communications Officer
Tel: 202.775.3242

Contact Paige Montfort
Media Relations Coordinator, External Relations
Tel: 202.775.3173
Related
Asia, Global Health, Global Health Policy Center, Health and Security, India, Infectious Disease, Tuberculosis

More from this blog

Blog Post
U.S.-Japan Dialogue: Strengthening the Partnership on Global Health
By J. Stephen Morrison
In Smart Global Health
July 25, 2017
Blog Post
Yellow Fever in Brazil: The Latest Global Health Security Threat
In Smart Global Health
June 23, 2017
Blog Post
Brazil's Sistema Único da Saúde (SUS): Caught in the Cross Fire
By Katherine E. Bliss
In Smart Global Health
June 21, 2017
Blog Post
GPEI’s Funding Decline Among Tedros’ Top Challenges as WHO Director-General
By Nellie Bristol
In Smart Global Health
June 9, 2017
Blog Post
Training the Informal Health Workforce in India
In Smart Global Health
May 22, 2017
Blog Post
What’s to Be Done to End the Opioid Epidemic?
In Smart Global Health
May 19, 2017
Blog Post
New Partnerships Needed after Ebola's Hard Lessons
By J. Stephen Morrison
In Smart Global Health
April 25, 2017
Blog Post
Leveraging the Latent Dedication of Health Care Workers in Nigeria
In Smart Global Health
January 23, 2017

Related Content

Blog Post
Solarizing India’s Healthcare System
In New Perspectives on Asia
July 30, 2021
Newsletter
U.S.-India Insight: India’s Blunt Economic Weapons Require Sharpening
By Richard M. Rossow
July 7, 2020
Report
Adapting Covid-19 Innovations to Accelerate Progress toward Meeting Global Tuberculosis Goals
By Katherine E. Bliss
November 12, 2021
Blog Post
Supporting India’s Healthcare Workers
In New Perspectives on Asia
September 7, 2021
Blog Post
U.S.-India Climate Agenda
By Neelima Jain
In Adapt & Advance: A Refreshed Agenda for U.S.-India Relations
February 11, 2021
Blog Post
Balancing Digital India and Vaccine Equity
In New Perspectives on Asia
July 7, 2021
Blog Post
U.S.-India Subnational Diplomacy
By Neelima Jain
In Adapt & Advance: A Refreshed Agenda for U.S.-India Relations
February 11, 2021
Blog Post
U.S.-India Healthcare Cooperation
By Anit Mukherjee
In Adapt & Advance: A Refreshed Agenda for U.S.-India Relations
February 11, 2021
Footer menu
  • Topics
  • Regions
  • Programs
  • Experts
  • Events
  • Analysis
  • Web Projects
  • Podcasts
  • iDeas Lab
  • Transcripts
  • About Us
  • Support Us
Contact CSIS
Email CSIS
Tel: 202.887.0200
Fax: 202.775.3199
Visit CSIS Headquarters
1616 Rhode Island Avenue, NW
Washington, DC 20036
Media Queries
Contact H. Andrew Schwartz
Chief Communications Officer
Tel: 202.775.3242

Contact Paige Montfort
Media Relations Coordinator, External Relations
Tel: 202.775.3173

Daily Updates

Sign up to receive The Evening, a daily brief on the news, events, and people shaping the world of international affairs.

Subscribe to CSIS Newsletters

Follow CSIS
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

All content © 2022. All rights reserved.

Legal menu
  • Credits
  • Privacy Policy
  • Reprint Permissions